As Aurora faces down an unsolicited takeover bid from one of many world’s largest hashish corporations, it has continued to broaden its attain in what it sees because the markets of the close to future.
This week, Aurora Hashish (ACB) introduced twin acquisitions within the UK value £2.1m, giving it direct possession of a licensed importer and wholesaler alongside a licensed pharmacy for the primary time in what it considers ‘a vital progress market’.
On August 19, 2026, the Canadian LP acquired 100% of the shares in Birmingham-based Internod Pharma and HAP Pharma in an all-cash deal.
Andreas Dotterweich, Aurora’s Senior Vice President, instructed Enterprise of Hashish that the acquisition was designed to shorten the gap between the corporate and the UK’s affected person inhabitants.
“It’s being lots nearer to the affected person,” he stated. “On the finish of the day, it’s affected person demand, and also you need to have a direct path to the affected person, and the direct path to market… it provides us additionally management and possession of the important thing import, distribution, and pharmacy capabilities.”
What has it acquired?
The 2 corporations Aurora now owns are intently related. Internode Pharma’s shareholders at incorporation included Hiren Arvindbhai Patel, a pharmacist, and Mithun Patel, an accountant, in keeping with Corporations Home filings. HAP Pharma, against this, was wholly owned by Hiren Patel alone till Mithun Patel was added to its possession register on August 18, 2026, at some point earlier than the deal was introduced.
Internode Pharma holds UK Wholesale Vendor’s Authorisation 58825, granted by the MHRA on August 14, 2024, protecting the import, holding and provide of prescription-only medicines, together with narcotic and psychotropic merchandise, from an working web site in Oldbury.
That licence is the important thing asset behind the acquisition, giving Aurora the appropriate to import and distribute medical hashish product into the UK with out routing them by a third-party wholesaler.
The corporate’s newest accounts present £30,872 in tools at price by March 2026, commerce collectors, and a small debtor e-book, although its turnover has by no means been made public.
HAP Pharma, in the meantime, is described as ‘a licensed pharmacy’, however has filed dormant firm accounts since incorporation in April 2020, suggesting no important buying and selling exercise.
Throughout Aurora’s first-quarter earnings name on August 5, Zuanic & Associates analyst Pablo Zuanic requested CEO Miguel Martin whether or not the corporate had been sluggish into the UK given how shortly rivals had constructed vertically built-in pharmacy and clinic networks there.
Martin stated in response: “I don’t suppose we’ve been sluggish in any respect. Our actual type of focus is on the genetics, the event and the manufacturing of those drugs. And within the UK, you’re proper, there’s been loads of motion on the scientific facet and on the pharmacy facet. These will not be areas of focus for us.”
Two weeks later, Aurora formally acquired the pharmacy and the importer for £2.1m in money. It’s unclear whether or not this was a current shift in priorities or whether or not it was merely cautious comms.
Dotterweich stated the deal gave Aurora ‘the important thing import, distribution, and pharmacy capabilities’ in a market Aurora already served by third events.
Following the expansion
Europe accounted for 47.5% of Aurora’s internet income within the quarter ended June 30, 2026, up from 33.7% a yr earlier, in keeping with the corporate’s newest monetary figures.
Canada’s share fell from 49.9% to 35.9% over the identical interval, as a lower to Veterans Affairs Canada’s hashish reimbursement fee, efficient April 1, 2026, pulled Canadian medical hashish income down 25% to CA$20.7m.
Germany drove the shift. Aurora’s worldwide medical hashish income rose 17% to CA$43.3m, which Martin instructed analysts meant ‘about 64% of our whole internet income was generated outdoors of Canada, up from 50% final yr,’ with progress concentrated in Germany particularly.
Simona King, Chief Monetary Officer of Aurora Hashish, described the quarter as reflecting ‘the strategic choices we now have made to reallocate our assets to give attention to world medical hashish alternatives,’ pointing to the Safari Flower Firm acquisition, an EU-GMP licensed Ontario cultivator purchased on April 14, 2026, as capability constructed particularly to provide ‘worldwide markets comparable to Germany, Poland and the UK.’
A UK focus
In a press launch saying its expanded UK operations, Martin stated it marked the most recent evolution of its long-term technique, transferring away from the Canadian adult-use markets in the direction of the medical hashish markets flourishing throughout Europe.
“We imagine that this transaction will permit us to completely leverage our operational, business and regulatory experience to broaden our market share, whereas additionally supporting a constant and dependable provide of high-quality medical hashish merchandise to UK sufferers,” Martin defined.
“Given the rising affected person demand, sturdy acceptance of our merchandise and more and more prescriptive regulatory requirements, the UK represents an thrilling alternative for us, and buying these corporations supplies Aurora with larger agility to extra reliably serve UK sufferers.”
Requested whether or not the deal would translate into decrease costs for sufferers, Dotterweich stated it was ‘a bit early to offer a concrete reply to that,’ however that it meant ‘higher entry for the sufferers, positively, additionally particularly with the pharmacy.’
On the ‘more and more prescriptive regulatory requirements’ Aurora Martin cited, Dotterweich argued Aurora’s platform is constructed to deal with regulatory shifts fairly than be threatened by them.
“It’s actually not straightforward to anticipate what’s occurring available in the market and laws,” he stated. “We as a medical hashish chief on this space, medical hashish is our playground… we are able to navigate that regulatory surroundings with our platform. And with what we did now within the UK, it’s strengthening our platform to function.”
That confidence extends to how central the UK now’s to Aurora’s wider progress plans. “The UK in itself is a vital progress marketplace for Aurora,” Dotterweich emphasised.
“A vital market with loads of focus, additionally strategically… the UK marketplace for us is basically vital when it comes to progress throughout the European and throughout the world setup.”
